Cardiology, Genetic Disease and Life Science

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Cardiology

Genetic Disease

Life Science

Tryngolza (Olezarsen) Becomes First FDA-Approved Drug for Familial Chylomicronemia Syndrome

XTalks

JANUARY 3, 2025

For the first time in the US, adults living with familial chylomicronemia syndrome (FCS) have an FDA-approved treatment option.

FDA Approval

FDA Approval Drugs Clinical Trials Clinical Trials

BridgeBio’s Attruby (Acoramidis): A New, More Potent TTR Stabilizer for ATTR-CM

XTalks

NOVEMBER 26, 2024

BridgeBio has been highly active in the genetic diseases space. Its investigational therapy infigratinib recently received Breakthrough Therapy designation, becoming the first-ever potential treatment for achondroplasia — a genetic condition affecting bone growth — to achieve this milestone.

Genetic Disease

Genetic Disease Genetics Protein Clinical Development

HFpEF vs. HFrEF: How To Improve Heart Failure Drug Development

XTalks

APRIL 15, 2021

Dr. Benoit Tyl, MD, FESC, medical and scientific director, cardiology at Servier, says that the disconnect between correlation and causality in cardiovascular disease trials is partially responsible for the lack of approved HFpEF therapies. However, these drugs have shown limited effectiveness in treating HFpEF.

Development

Development Drugs Genome Genomics

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Clinical Research Informer

Tryngolza (Olezarsen) Becomes First FDA-Approved Drug for Familial Chylomicronemia Syndrome

BridgeBio’s Attruby (Acoramidis): A New, More Potent TTR Stabilizer for ATTR-CM

HFpEF vs. HFrEF: How To Improve Heart Failure Drug Development

Webinars

Stay Connected